Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis


120 patients of biopsy proven NASH will be randomized into two groups. Cases group will receive combination of pentoxiphylline and Vitamin E, and control group will receive only Vitamin E.

Full Title of Study: “A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: November 2013

Detailed Description

The investigators plan to randomise 120 patients of biopsy proven NASH into cases and control groups.

Baseline investigations:

Clinical characteristics

- Age

- Gender

- Anthropometry (BMI, waist circumference, waist- hip ratio, triceps skin fold thickness, mid arm circumference)

- Alcohol intake should be nil

Laboratory characteristics

- Hemogram, INR, KFT

- LFT (especially ALT, GGT) , APRI (AST to platelet ratio)

- Fasting Lipid Profile

- Other possible etiologies of liver disease (viral markers, ferritin, ANA, IgG, ceruloplasmin )


- Serum uric acid levels Liver stiffness

- Fibroscan

- MR elastography Radiological characteristics

- USG abdomen Variceal status by UGI endoscopy Alpha fetoprotein Pro- inflammatory markers

- TNF-alpha, IL-6, adiponectin, leptin and osteopontin Liver biopsy and NAS score


  • Drug: pentoxiphylline and Vitamin E
    • Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
  • Drug: Vitamin E
    • Patients in control group will receive vitamin E 800 IU/day

Arms, Groups and Cohorts

  • Experimental: pentoxiphylline and Vitamin E
  • Active Comparator: Vitamin E

Clinical Trial Outcome Measures

Primary Measures

  • histological outcome in the form of improvement or non- progression in hepatocyte injury and fibrosis (NAS score).
    • Time Frame: 3 Months

Secondary Measures

  • Response in form of anthropometry , HOMA-IR, fasting lipid profiles, biochemical response in form of normalization of ALT and AST levels and reduction in uric
    • Time Frame: 3 Months

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 to 70 years
  • Persistently abnormal ALT >1.2 times upper limit of normal
  • Histological evidence of NASH/cirrhosis on liver biopsy. ( The minimal criteria for diagnosis of NASH included the presence of lobular inflammation and either ballooning of cells or perisinusoidal or pericellular fibrosis in Zone 3 of the hepatic acinus)

Exclusion Criteria

  • A known case of Type 2 diabetes mellitus on treatment
  • Alcohol intake of more than 40gm / week
  • If they had evidence of cirrhosis with significant portal hypertension
  • Ongoing total parenteral nutrition/ jejunal-ileal bypass
  • Other known liver disease (Hepatitis A to E, autoimmune liver disease, Wilson's disease, alpha 1 antitrypsin deficiency and hemochromatosis)
  • Medication like estrogens, amiodarone, MTx, tamoxifen, ATT
  • Pregnancy or lactation
  • Hypersensitivity to methylxanthines (e.g., caffeine, theophylline, theobromine )
  • Recent retinal/cerebral hemorrhage
  • Acute myocardial infarction or severe cardiac arrhythmias
  • Impaired renal function
  • Hypothyroidism

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institute of Liver and Biliary Sciences, India
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shiv Kumar Sarin, MD,DM, Study Director, Institute of Liver & Biliary Sciences (ILBS)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.